Polivy 140mg Injection (Polatuzumab Vedotin)

Polivy 140mg Injection is a prescription-based targeted anticancer medicine used in the treatment of certain types of B-cell non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma (DLBCL). The active ingredient of Polivy is polatuzumab vedotin, which belongs to the class of medications known as antibody-drug conjugates. It works by blocking CD79b protein found on B cells. After the binding, the medicine releases its cytotoxic component into the cell. This action leads to the cell's decreased ability to divide and can ultimately lead to the death of the cancer cell. It may be prescribed for patients with previously untreated DLBCL or in combination with other medicines.

The injection is administered as an intravenous infusion by a qualified doctor in a hospital or clinical setting. The doctor determines the dosage of the Polatuzumab 140mg injection according to the type of cancer, treatment regimen, age, and overall health of the patient. It should not be self-administered. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include tiredness, diarrhea, nausea, fever, decreased appetite, low blood-cell counts, peripheral neuropathy, and infections. A few patients can undergo severe side effects, including severe infections, significant reduction in blood-cell counts, liver problems, and peripheral nerve damage. Most of the Polatuzumab 140mg injection side effects can leave when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

Pregnancy should be avoided during treatment, and appropriate contraception should be taken. Patients must list all medicines, supplements, and herbal products that they are taking. The Polatuzumab 140mg injection must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Diffuse large B-cell lymphoma

The human body shows undesired symptoms after taking the Polivy 140mg injection (polatuzumab vedotin). Usually, they disappear with time as the body adjusts to the medicine. These side effects do not need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Common side effects

• Neutropenia

• Anemia

• Thrombocytopenia

• Leukopenia

• Lymphopenia

• Diarrhea

• Nausea

• Vomiting

• Fatigue

• Fever

• Decreased appetite

• Peripheral neuropathy

• Dizziness

• Headache

• Cough

• Respiratory infections

 Serious side effects

• Tumor lysis syndrome

• Liver Toxicity

• Severe Infections

Polivy is administered only by intravenous infusion by a qualified doctor. The dose is determined by the doctor according to the type of cancer, treatment regimen, age, and overall health of the patient. The injection should not be self-administered, and doctors advise the patient to be monitored for infusion-related reactions during the treatment.

• Take the missed dose as soon as you remember but ensure that it is not close to the next scheduled dose

• If it is close to the next dose, skip the dose

• Avoid overdose of the medicine

Manual, C. P. Polatuzumab Vedotin-piiq (eg, Polivy).
Fala, L. (2020). Polivy (Polatuzumab Vedotin-piiq), Novel Antibody–Drug Conjugate, Approved for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Recommendation, C. R. Polatuzumab Vedotin (Polivy).
Yip, Victor, et al. "Preclinical characterization of the distribution, catabolism, and elimination of a polatuzumab vedotin-piiq (POLIVY®) antibody–drug conjugate in Sprague Dawley rats." Journal of Clinical Medicine 10.6 (2021): 1323.
Deeks, E. D. (2019). Polatuzumab Vedotin: First Global Approval: ED Deeks. Drugs, 79(13), 1467-1475.
Tilly, Hervé, et al. "Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma." New England Journal of Medicine 386.4 (2022): 351-363.